Literature DB >> 30305455

T cells take aim at a ubiquitous autoantigen in multiple sclerosis.

Joseph J Sabatino1, Scott S Zamvil2.   

Abstract

CD4+ T cells from multiple sclerosis lesions target a ubiquitous self-antigen that is shared by gut commensal bacteria (Planas et al, this issue).
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30305455     DOI： 10.1126/scitranslmed.aau8826

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  5 in total

1.  The immune signatures of multiple sclerosis: Lessons from twin studies.

Authors:  Pablo Villoslada; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-14       Impact factor: 11.205

2.  PO-322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity.

Authors:  Yi Lai; Xing-Yan Luo; Hui-Jie Guo; Si-Yu Wang; Jing Xiong; Shu-Xia Yang; Li-Mei Li; Qiang Zou; Chun-Fen Mo; Yan-Tang Wang; Yang Liu
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

3.  Gut Microbiota as a Potential Predictive Biomarker in Relapsing-Remitting Multiple Sclerosis.

Authors:  Vicente Navarro-López; María Ángeles Méndez-Miralles; Rosa Vela-Yebra; Ana Fríes-Ramos; Pedro Sánchez-Pellicer; Beatriz Ruzafa-Costas; Eva Núñez-Delegido; Humberto Gómez-Gómez; Sara Chumillas-Lidón; Jose A Picó-Monllor; Laura Navarro-Moratalla
Journal:  Genes (Basel)       Date:  2022-05-23       Impact factor: 4.141

Review 4.  Epstein-Barr Virus and Multiple Sclerosis.

Authors:  Gunnar Houen; Nicole Hartwig Trier; Jette Lautrup Frederiksen
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 5.  Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy.

Authors:  Satyakam Bhagavati
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.